Evaluation of antitumor and anticancer activity of 4-amino benzoic benzoyl benzimidazole in ehrlich’s ascites carcinoma induced male swiss mice
Abstract
Experimental tumors by Ehrlich ascites carcinoma have gained attention for the induction of carcinoma in swiss albino mice. Cancer is one of the most emerging life threatening factors in developing countries. Presently various benzimidazole derivatives have drawn the attention as most active heterocyclic compounds with various pharmacological activities. In the present study, the bendimidazole derivative, 4-amino benzoic benzoyl benzimidazole (4ABBB) was synthesized and acute toxicity (LD50= 250mg/kg body weight which was administered orally) of 4ABBB on swiss albino mice were determined. The protocol started with the tumor induction in animals by inoculating 2×106 tumor cells and then they are divided into five groups of ten animals each. After 24 h of transplanting, the drug was administered intraperitoneally at a dose of 20mg/kg and 10mg/kg body weight and 20 mg/kg bodyweight 5-Fluorouracil as reference drug. At the tenth day, half of the 18 h fasted animals were sacrificed and i.p fluid was collected to determine tumor volume, weight, viable (cancer) and nonviable (dead) cell count. Blood was collected to determine hemoglobin concentration, RBC count, WBC count and percentage of packed cell volume. Half of the remaining animals in each group were kept for assessing percentage increase in life span (ILS) and mean survival time. 4ABBB showed a significant improvement in a dose dependent manner especially, reduction in viable cell count (P< 0.001), RBC count and hemoglobin concentration and improvement in percentage of life span which is comparable with 5-Fluorouracil.
Keywords:
4-amino benzoic benzoyl benzimidazole, Cancer, Carcinoma, Ehrlich ascites carcinoma
Downloads
Download data is not yet available.
References
Achar KCS, Hosamani KM and Seetharamareddy HR. In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. European Journal of Medicinal Chemistry 2010; 45:2048–2054.
2. Alp M, Goker H, Brun R and Yıldız S. Synthesis and anti-parasitic and anti-fungal evaluation of 20- arylsubsti-tuted-1H, 10H-[2, 50] bisbenzimidazolyl-5-carboxamidines. European Journal of Medicinal Chemistry 2009; 44:2002-2008.
3. Bala A, Kar B, Haldar PK, Mazumder UK and Bera S. Evaluation of anticancer activity of Cleome gynandra on Ehrlich’s Ascites Carcinoma treated mice. Journal of Ethnopharmacology 2010; 129:131-134.
4. Camacho J, Barazarte A, Gamboa N, Rodrigues J, Rojas R, Vaisberg A, Gilman R and Charris J. Synthesis and biological evaluation of benzimidazole-5-Carbohydrazide derivatives as anti-malarial, cytotoxic and anti-tubercular agents. Bioorganic & Medicinal Chemistry 2011; 19:2023–2029.
5. Carter MW, Matrone G and Metzler C. Estimation of the Life Span of Red blood Cells in the Growing Animal in Different Nutritional States. Journal of General Physiology 1965; 49:57-67.
6. Chen A, Bookstein JJ and Meldrum DR. Diagnosis of a testosterone-secreting adrenal adenoma by selective venous catheterization. Fertility and Sterility 1991; 55:1202-1203.
7. De A, Singh MF, Singh V, Ram V and Bisht S. Treatment effect of L-Norvaline on the sexual performance of male rats with streptozotocin induced diabetes. European Journal of Pharmacology 2016; 771:247-254.
8. Demirayaka S, Kayagilb I and Yurttasc L. Microwave supported synthesis of some novel 1, 3-Diarylpyrazino [1, 2-a] benzimidazole derivatives and investigation of their anticancer activities. European Journal of Medicinal Chemistry 2011; 46:411-416.
9. Diasio RB and Harris BE. Clinical Pharmacology of 5-fluorouracil. Clinical Pharmacokinetics 1989; 16:215-237.
10. Dubey PK, Naidu A, Reddy PV, Kumar ND and Vineel BG. Studies on synthesis of unsymmetrical 2,21- bisbenzimidazole sulphides of pharmacological interest. Indian Journal of Chemistry 2008; 47:1443-1446.
11. Estrela MJ, Hernandez R, Terradez P, Asensi M, Puertes R and Vina J. Regulation of Glutathione Metabolism in Ehrlich Ascites Tumour Cells. Biochemical Journal 1992; 286:257-262.
12. Gardiner JM, Loyns CR, Burke A, Khan A and Mahmood N. Synthesis and HIV-1 inhibition of novel benzimidazole derivatives. Bioorganic & Medicinal Chemistry Letters 1995; 5:1251-1254.
13. Grune T, Siems W, Uhlig R and Jakstadt M. Adenine Metabolism of Ehrlich Mouse Ascites Cells in Proliferating and Resting Phases of Tumor Growth. International Journal of Biochemistry 1992; 26:199-209.
14. Haldar S, Karmakar I, Chakraborty M, Ahmad D and Haldar PK. Antitumor Potential of Thevetia peruviana on Ehrlich’s Ascites Carcinoma– Bearing Mice. Journal of Environmental Pathology, Toxicology and Oncology 2015; 34:105–113.
15. Hernández-Luis F, Hernández-Campos A, Castillo R, Navarrete-Vázquez G, Soria-Arteche O, Hernandez Hernandez M and Yépez-Mulia L. Synthesis and biological activity of 2-(trifluoromethyl)-1Hbenzimidazole derivatives against some protozoa and Trichinella spiralis. European Journal of Medicinal Chemistry 2010; 45:3135-3141.
16. Kalirajan R, Rathore L, Jubie S, Gowramma B, Gomathy S and Sankar S. Microwave assisted synthesis of some novel pyrazole substitutedbenzimidazoles and evaluation of their biological activities. Indian Journal of Chemistry 2011; 50:1794-1799.
17. Kazimierczuk Z, Upcroft JA, Upcroft P, Gorska A, Starosciak B and Laundy A. Synthesis of antiprotozoal and antibacterial activity of nitro and halogeno substituted benzimidazole derivatives. Acta Biochimica Polonica 2002; 49:185- 195.
18. Kennedy DO, Kojima A, Hasuma T, Yano Y, Otani S and Matsui YI. Growth inhibitory effect of green tea extract and (–)-epigallocatechin in Ehrlich Ascites tumor cells involves a cellular thiol-dependent activation of mitogenic-activated protein kinases. Chemico-Biological Interactions 2001; 134:113–133.
19. Kumar BVS, Vaidya SD, Kumar RV, Bhirud SB and Mane RB. Synthesis and anti-bacterial activity of some novel 2-(6-fluorochroman-2-yl)-1-alkyl/acyl/aroyl-1H-benzimidazoles. European Journal of Medicinal Chemistry 2006; 41:599–604.
20. Lalee A, Pal P, Bhattacharaya B and Samanta A. Evaluation of Anticancer activity of Aerva Sanguinolenta (L.) (Amaranthaceae) on Ehrlich’s Ascites cell induced Swiss Mice. International Journal of Drug Development and Research 2012; 4:203-209.
21. Lazebnik YA, Medvedeva DN and Zenin VV. Reversible G2 Block in the Cell Cycle of Ehrlich Ascites Carcinoma Cells. Experimental Cell Research 1991; 195:247-254.
22. Lobo C, Ruiz-Bellido, MA, Aledo JC, Marquez J, De Castro IN and Alonso FJ. Inhibition of Glutaminase Expression by Antisense mRNA Decreases Growth and Tumourigenicity of Tumour Cells. Biochemical Journal 2000; 348:257-261.
23. Mazumder UK, Gupta M, Maity M and Mukherjee M. Antitumor activity of Gygrophila spinosa on Erlich Ascites Carcinoma and sarcoma-180 induced mice. Indian Journal of Experimental Biology 1997; 35:473–477.
24. Sugumaran M and Kumar YM. Synthesis and Biological Activity of Novel 2, 5- Disubstituted Benzimidazole Derivatives. International Journal of Pharmaceutical Sciences and Drug Research 2012; 4:80-83.
25. Van den Heuvel MJ, Clark DG, Fielder RJ, Koundakjian PP, Oliver GJA, Pelling D, Tomlinson NJ and Walker. The international validation of a fixed-dose procedure as an alternative to the classical LD50 test. Food and Chemical Toxicology 1990; 28:469-482
26. Nawrocka W, Sztuba B, Kowalska MW, Liszkiewicz H, Wietrzyk J, Nasulewicz A, Pełczynska M and Opolski A. Synthesis and antiproliferative activity in vitro of 2-aminobenzimidazole derivatives. Farmaco Sci 2004; 59:83–91.
27. Ng RA, Guan J, Alford VC, Lanter JC, Allan GF, Sbriscia T, Linton O, Lundeen SG and Sui Z. Synthesis and SAR of potent and selective androgen receptor antagonists: 5, 6 dichloro Benzimidazole derivatives. Bioorganic and Medicinal Chemistry Letters 2007; 17:784-788.
28. Oberling C and Guerin M. The role of viruses in the production of cancer. Advances in Cancer Research 1954; 2:353-423.
29. Ozaslan M, Karagoz ID, Kilic IH and Guldur ME. Ehrlich ascites carcinoma. African Journal of Biotechnology 2011; 10:2375-2378.
30. Ozkay Y, Tunali Y, Karaca H and Isikdag I. Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazones moiety. European Journal of Medicinal Chemistry 2010; 45:3293-3298.
31. Radha Y, Manjula A, Reddy BM and Rao BV. Synthesis and biological activity of novel Benzimidazoles’, Indian Journal of Chemistry 2011; 50:1762-1773.
32. Ramla MM, Omar MA, Khamry AM and Diwani HI. Synthesis and antitumor activity of 1-substituted-2-methyl-5-nitrobenzimidazoles. Bioorganic and Medicinal Chemistry 2006; 14:7324-7332.
33. Saluja MS, Sangameswaran B and Sharma A. Cytotoxic activity of Vitex Negundo against Ehrlich Ascites Carcinoma (EAC) in mice. International Journal of Pharm Tech Research 2010; 2:1369-1375.
34. Santi DV, McHenry CS and Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13:471-481
35. Siems WG, Grune T, Schmidt H, Tikhonov YV and Pimenov MA. Purine Nucleotide Levels in Host Tissues of Ehrlich Ascites Tumor Bearing Mice in different growth phases of the Tumor. Cancer Research 1993; 53:5143-5147.
36. Skog S, He Q and Tribukait B. Lack of Correlation Between Thymidine Kinase Activity and Changes of DNA Synthesis With Tumour Age: An In Vivo Study in Ehrlich Ascites Tumour. Cell and Tissue Kinetics 1990; 23:603-617.
37. Song Z, Varani J and Goldstein IJ. Differences in Cell Surface Carbohydrates and in Laminin and Fibronectin Synthesis Between Adherent and Non-adherent Ehrlich Ascites Tumor Cells. International Journal of Cancer 1993; 55:1029-1035.
38. Miao P, Sheng S, Sun X, Liu J and Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. International Union of Biochemistry and Molecular Biology Life 2013; 65:904-910.
39. Szikla K, Pokorny E, Hullan L and Holczinger L. Variations of Thymidine Kinase Activity and DNA Content in Ehrlich and L121o Ascites Tumor Cells during Tumor Growth. Cancer biochemistry biophysics 1981; 5:259-264.
40. Taher AT, Khalil NA, Ahmed EM and Ragab YM. Synthesis of certain 2-substituted-1-H-benzimidazole derivatives as antimicrobial and cytotoxic agent. Chemical and Pharmaceutical Bulletin 2012; 60:778-784.
41. Tannock IF. A Comparison of Cell Proliferation parameters in Solid and Ascites Ehrlich Tumors. Cancer Research 1969; 29:1527-1534.
42. Navarrete-Vázquez G, Cedillo R, Hernández-Campos A, Yepez L, Hernández-Luis FJ, Valdéz R, Morales R, Cortés M and Castillo R. Synthesis and antiparasitic activity of 2-(trifluoromethyl) benzimidazole derivatives. Bioorganic and Medicinal Chemistry Letters 2001; 11:187–190.
43. Vinuela JE, Rodriguez R, Gil J, Coll J, Concha E and Subiza JL. Antigen Sheddıng Vs. Development of Natural Suppressor Cells As Mechanism of Tumor Escape in Mice Bearing Ehrlich Tumor. International Journal of Cancer 1991; 47:86-91.
44. Vitale G, Carta A, Loriga M, Paglietti G, Colla P, Busonera B, Collu D and Loddo R. 2-Arylbenzimidazoles as Anti-viral and Anti-proliferative Agents-Part 1. Medicinal Chemistry 2008; 4:605-615.
45. Wohlhueter RM, Mclvor RS and Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. Journal of Cellular Physiology 1980; 104:309-319.
46. Yadav S, Kumar P, Clercq ED, Balzarini J, Pannecouque C, Dewan SK and Narasimhan B. 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: Synthesis, anti-microbial activity, QSAR studies, and anti-viral evaluation. European Journal of Medicinal Chemistry 2010; 45:5985-5997.
2. Alp M, Goker H, Brun R and Yıldız S. Synthesis and anti-parasitic and anti-fungal evaluation of 20- arylsubsti-tuted-1H, 10H-[2, 50] bisbenzimidazolyl-5-carboxamidines. European Journal of Medicinal Chemistry 2009; 44:2002-2008.
3. Bala A, Kar B, Haldar PK, Mazumder UK and Bera S. Evaluation of anticancer activity of Cleome gynandra on Ehrlich’s Ascites Carcinoma treated mice. Journal of Ethnopharmacology 2010; 129:131-134.
4. Camacho J, Barazarte A, Gamboa N, Rodrigues J, Rojas R, Vaisberg A, Gilman R and Charris J. Synthesis and biological evaluation of benzimidazole-5-Carbohydrazide derivatives as anti-malarial, cytotoxic and anti-tubercular agents. Bioorganic & Medicinal Chemistry 2011; 19:2023–2029.
5. Carter MW, Matrone G and Metzler C. Estimation of the Life Span of Red blood Cells in the Growing Animal in Different Nutritional States. Journal of General Physiology 1965; 49:57-67.
6. Chen A, Bookstein JJ and Meldrum DR. Diagnosis of a testosterone-secreting adrenal adenoma by selective venous catheterization. Fertility and Sterility 1991; 55:1202-1203.
7. De A, Singh MF, Singh V, Ram V and Bisht S. Treatment effect of L-Norvaline on the sexual performance of male rats with streptozotocin induced diabetes. European Journal of Pharmacology 2016; 771:247-254.
8. Demirayaka S, Kayagilb I and Yurttasc L. Microwave supported synthesis of some novel 1, 3-Diarylpyrazino [1, 2-a] benzimidazole derivatives and investigation of their anticancer activities. European Journal of Medicinal Chemistry 2011; 46:411-416.
9. Diasio RB and Harris BE. Clinical Pharmacology of 5-fluorouracil. Clinical Pharmacokinetics 1989; 16:215-237.
10. Dubey PK, Naidu A, Reddy PV, Kumar ND and Vineel BG. Studies on synthesis of unsymmetrical 2,21- bisbenzimidazole sulphides of pharmacological interest. Indian Journal of Chemistry 2008; 47:1443-1446.
11. Estrela MJ, Hernandez R, Terradez P, Asensi M, Puertes R and Vina J. Regulation of Glutathione Metabolism in Ehrlich Ascites Tumour Cells. Biochemical Journal 1992; 286:257-262.
12. Gardiner JM, Loyns CR, Burke A, Khan A and Mahmood N. Synthesis and HIV-1 inhibition of novel benzimidazole derivatives. Bioorganic & Medicinal Chemistry Letters 1995; 5:1251-1254.
13. Grune T, Siems W, Uhlig R and Jakstadt M. Adenine Metabolism of Ehrlich Mouse Ascites Cells in Proliferating and Resting Phases of Tumor Growth. International Journal of Biochemistry 1992; 26:199-209.
14. Haldar S, Karmakar I, Chakraborty M, Ahmad D and Haldar PK. Antitumor Potential of Thevetia peruviana on Ehrlich’s Ascites Carcinoma– Bearing Mice. Journal of Environmental Pathology, Toxicology and Oncology 2015; 34:105–113.
15. Hernández-Luis F, Hernández-Campos A, Castillo R, Navarrete-Vázquez G, Soria-Arteche O, Hernandez Hernandez M and Yépez-Mulia L. Synthesis and biological activity of 2-(trifluoromethyl)-1Hbenzimidazole derivatives against some protozoa and Trichinella spiralis. European Journal of Medicinal Chemistry 2010; 45:3135-3141.
16. Kalirajan R, Rathore L, Jubie S, Gowramma B, Gomathy S and Sankar S. Microwave assisted synthesis of some novel pyrazole substitutedbenzimidazoles and evaluation of their biological activities. Indian Journal of Chemistry 2011; 50:1794-1799.
17. Kazimierczuk Z, Upcroft JA, Upcroft P, Gorska A, Starosciak B and Laundy A. Synthesis of antiprotozoal and antibacterial activity of nitro and halogeno substituted benzimidazole derivatives. Acta Biochimica Polonica 2002; 49:185- 195.
18. Kennedy DO, Kojima A, Hasuma T, Yano Y, Otani S and Matsui YI. Growth inhibitory effect of green tea extract and (–)-epigallocatechin in Ehrlich Ascites tumor cells involves a cellular thiol-dependent activation of mitogenic-activated protein kinases. Chemico-Biological Interactions 2001; 134:113–133.
19. Kumar BVS, Vaidya SD, Kumar RV, Bhirud SB and Mane RB. Synthesis and anti-bacterial activity of some novel 2-(6-fluorochroman-2-yl)-1-alkyl/acyl/aroyl-1H-benzimidazoles. European Journal of Medicinal Chemistry 2006; 41:599–604.
20. Lalee A, Pal P, Bhattacharaya B and Samanta A. Evaluation of Anticancer activity of Aerva Sanguinolenta (L.) (Amaranthaceae) on Ehrlich’s Ascites cell induced Swiss Mice. International Journal of Drug Development and Research 2012; 4:203-209.
21. Lazebnik YA, Medvedeva DN and Zenin VV. Reversible G2 Block in the Cell Cycle of Ehrlich Ascites Carcinoma Cells. Experimental Cell Research 1991; 195:247-254.
22. Lobo C, Ruiz-Bellido, MA, Aledo JC, Marquez J, De Castro IN and Alonso FJ. Inhibition of Glutaminase Expression by Antisense mRNA Decreases Growth and Tumourigenicity of Tumour Cells. Biochemical Journal 2000; 348:257-261.
23. Mazumder UK, Gupta M, Maity M and Mukherjee M. Antitumor activity of Gygrophila spinosa on Erlich Ascites Carcinoma and sarcoma-180 induced mice. Indian Journal of Experimental Biology 1997; 35:473–477.
24. Sugumaran M and Kumar YM. Synthesis and Biological Activity of Novel 2, 5- Disubstituted Benzimidazole Derivatives. International Journal of Pharmaceutical Sciences and Drug Research 2012; 4:80-83.
25. Van den Heuvel MJ, Clark DG, Fielder RJ, Koundakjian PP, Oliver GJA, Pelling D, Tomlinson NJ and Walker. The international validation of a fixed-dose procedure as an alternative to the classical LD50 test. Food and Chemical Toxicology 1990; 28:469-482
26. Nawrocka W, Sztuba B, Kowalska MW, Liszkiewicz H, Wietrzyk J, Nasulewicz A, Pełczynska M and Opolski A. Synthesis and antiproliferative activity in vitro of 2-aminobenzimidazole derivatives. Farmaco Sci 2004; 59:83–91.
27. Ng RA, Guan J, Alford VC, Lanter JC, Allan GF, Sbriscia T, Linton O, Lundeen SG and Sui Z. Synthesis and SAR of potent and selective androgen receptor antagonists: 5, 6 dichloro Benzimidazole derivatives. Bioorganic and Medicinal Chemistry Letters 2007; 17:784-788.
28. Oberling C and Guerin M. The role of viruses in the production of cancer. Advances in Cancer Research 1954; 2:353-423.
29. Ozaslan M, Karagoz ID, Kilic IH and Guldur ME. Ehrlich ascites carcinoma. African Journal of Biotechnology 2011; 10:2375-2378.
30. Ozkay Y, Tunali Y, Karaca H and Isikdag I. Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazones moiety. European Journal of Medicinal Chemistry 2010; 45:3293-3298.
31. Radha Y, Manjula A, Reddy BM and Rao BV. Synthesis and biological activity of novel Benzimidazoles’, Indian Journal of Chemistry 2011; 50:1762-1773.
32. Ramla MM, Omar MA, Khamry AM and Diwani HI. Synthesis and antitumor activity of 1-substituted-2-methyl-5-nitrobenzimidazoles. Bioorganic and Medicinal Chemistry 2006; 14:7324-7332.
33. Saluja MS, Sangameswaran B and Sharma A. Cytotoxic activity of Vitex Negundo against Ehrlich Ascites Carcinoma (EAC) in mice. International Journal of Pharm Tech Research 2010; 2:1369-1375.
34. Santi DV, McHenry CS and Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13:471-481
35. Siems WG, Grune T, Schmidt H, Tikhonov YV and Pimenov MA. Purine Nucleotide Levels in Host Tissues of Ehrlich Ascites Tumor Bearing Mice in different growth phases of the Tumor. Cancer Research 1993; 53:5143-5147.
36. Skog S, He Q and Tribukait B. Lack of Correlation Between Thymidine Kinase Activity and Changes of DNA Synthesis With Tumour Age: An In Vivo Study in Ehrlich Ascites Tumour. Cell and Tissue Kinetics 1990; 23:603-617.
37. Song Z, Varani J and Goldstein IJ. Differences in Cell Surface Carbohydrates and in Laminin and Fibronectin Synthesis Between Adherent and Non-adherent Ehrlich Ascites Tumor Cells. International Journal of Cancer 1993; 55:1029-1035.
38. Miao P, Sheng S, Sun X, Liu J and Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. International Union of Biochemistry and Molecular Biology Life 2013; 65:904-910.
39. Szikla K, Pokorny E, Hullan L and Holczinger L. Variations of Thymidine Kinase Activity and DNA Content in Ehrlich and L121o Ascites Tumor Cells during Tumor Growth. Cancer biochemistry biophysics 1981; 5:259-264.
40. Taher AT, Khalil NA, Ahmed EM and Ragab YM. Synthesis of certain 2-substituted-1-H-benzimidazole derivatives as antimicrobial and cytotoxic agent. Chemical and Pharmaceutical Bulletin 2012; 60:778-784.
41. Tannock IF. A Comparison of Cell Proliferation parameters in Solid and Ascites Ehrlich Tumors. Cancer Research 1969; 29:1527-1534.
42. Navarrete-Vázquez G, Cedillo R, Hernández-Campos A, Yepez L, Hernández-Luis FJ, Valdéz R, Morales R, Cortés M and Castillo R. Synthesis and antiparasitic activity of 2-(trifluoromethyl) benzimidazole derivatives. Bioorganic and Medicinal Chemistry Letters 2001; 11:187–190.
43. Vinuela JE, Rodriguez R, Gil J, Coll J, Concha E and Subiza JL. Antigen Sheddıng Vs. Development of Natural Suppressor Cells As Mechanism of Tumor Escape in Mice Bearing Ehrlich Tumor. International Journal of Cancer 1991; 47:86-91.
44. Vitale G, Carta A, Loriga M, Paglietti G, Colla P, Busonera B, Collu D and Loddo R. 2-Arylbenzimidazoles as Anti-viral and Anti-proliferative Agents-Part 1. Medicinal Chemistry 2008; 4:605-615.
45. Wohlhueter RM, Mclvor RS and Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. Journal of Cellular Physiology 1980; 104:309-319.
46. Yadav S, Kumar P, Clercq ED, Balzarini J, Pannecouque C, Dewan SK and Narasimhan B. 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: Synthesis, anti-microbial activity, QSAR studies, and anti-viral evaluation. European Journal of Medicinal Chemistry 2010; 45:5985-5997.
Published
31/12/2016
Statistics
91 Views | 76 Downloads
Citatons
How to Cite
Samanta, A., Maji, H. S., Abhijit De, & Kar, S. K. (2016). Evaluation of antitumor and anticancer activity of 4-amino benzoic benzoyl benzimidazole in ehrlich’s ascites carcinoma induced male swiss mice. Journal of Innovations in Applied Pharmaceutical Science (JIAPS), 1(4), 01-09. Retrieved from https://www.saapjournals.org/index.php/jiaps/article/view/183
Issue
Section
Research Article(S)
Copyright © Author(s) retain the copyright of this article.
.